(Note: Solta Medical Corp. withdrew its IPO plans in an SEC filing dated Nov. 21, 2022. No terms had been set, but the IPO proceeds were estimated at up to $200 million. Solta Medical Corp. filed its S-1 on Feb. 8, 2022. The company’s parent, Bausch Health Companies Inc. (BHC) planned to spin off Solta Medical by offering all stock in the IPO, and Solta Medical Corp. would NOT have received any proceeds from the IPO. Solta Medical had submitted confidential IPO documents to the SEC on Sept. 3, 2021.)

We believe we are a leading global aesthetic medical device company focused on the development, manufacture and sale of innovative technologies that provide aesthetic and therapeutic benefits. Since the launch of our first commercial Thermage^® product in 2002, we have pioneered products that have advanced the field of aesthetic medical devices, including building a portfolio of over 200 patents worldwide. With one of the longest track records in the aesthetic medical device industry, our category-leading brands – Thermage^®, Clear + Brilliant^®, Fraxel^® and VASER^® – are well-respected and well-known to consumers of skin and body aesthetic treatments. Our portfolio of clinically proven energy-based aesthetic medical devices addresses a range of fast-growing treatment categories, including skin tightening, skin resurfacing, and body contouring, and the majority of our revenue from these technologies is derived from non- and minimally-invasive procedures. We offer our global customer base of dermatologists, plastic surgeons, aesthetic physicians and medical spa practitioners a compelling value proposition and return on investment to build and grow their respective practices. Our focus on developing cutting-edge technologies to better meet the needs of consumers coupled with the compelling value we offer to our customer partners has allowed us to build a significant global footprint, with an installed base of more than 13,800 systems and presence in approximately 50 countries as of Dec. 31, 2020.

(Background Note: This is an initial public offering of common shares of Solta Medical Corporation. All of our common shares are currently held by Bausch Health Companies Inc. (“BHC”). BHC is selling all of the common shares offered hereby. We are not selling any of the common shares in this offering and will NOT receive any proceeds from the sale of the common shares. After the IPO, BHC will continue to own a majority of the voting power of our common shares and we will be a “controlled company.”)